about
Autophagy and urothelial carcinoma of the bladder: A reviewThe urgent need to recover MHC class I in cancers for effective immunotherapyTreatment options in non-muscle-invasive bladder cancer after BCG failureApplications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapyTopical and systemic immunoreaction triggered by intravesical chemotherapy in an N-butyl-N-(4-hydroxybutyl) nitorosamine induced bladder cancer mouse model.Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion.Metachronous adenoid cystic carcinoma in the peripheral lung and at base of the tongueEfficacy of intravesical Bacillus Calmette-Guérin therapy against tumor immune escape in an orthotopic model of bladder cancer.Intravesical chitosan/interleukin-12 immunotherapy induces tumor-specific systemic immunity against murine bladder cancerAlterations in ubiquitin ligase Siah-2 and its corepressor N-CoR after P-MAPA immunotherapy and anti-androgen therapy: new therapeutic opportunities for non-muscle invasive bladder cancer.Bacillus Calmette-Guerin therapy after the second transurethral resection significantly decreases recurrence in patients with new onset high-grade T1 bladder cancer.Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: mechanism of action of P-MAPA biological response modifier.Rates of MAGE-A3 and PRAME expressing tumors in FFPE tissue specimens from bladder cancer patients: potential targets for antigen-specific cancer immunotherapeutics.Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer.Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.Nonmuscle invasive bladder cancer: a primer on immunotherapy.Potential therapeutic strategies for non - muscle invasive bladder cancer based on association of intravesical immunotherapy with p - mapa and systemic administration of cisplatin and doxorubicin.Synergistic effect between cisplatin and sunitinib malate on human urinary bladder-cancer cell lines.Treatment efficacy and tolerability of intravesical bacillus Calmette-Guerin (BCG)-RIVM strain: induction and maintenance protocol in high grade and recurrent low grade non-muscle invasive bladder cancer (NMIBC).Cytokines as effectors and predictors of responses in the treatment of bladder cancer by bacillus Calmette-Guérin.Recombinant bacillus Calmette-Guérin in urothelial bladder cancer immunotherapy: current strategies.Recombinant Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer.Local immunotherapy based on agonistic CD40 antibodies effectively inhibits experimental bladder cancer.Future directions in bladder cancer immunotherapy: towards adaptive immunity.From inflammation to cancer.Preclinical efficacy and safety of the Ty21a vaccine strain for intravesical immunotherapy of non-muscle-invasive bladder cancer.H2O2 generation by bacillus Calmette-Guérin induces the cellular oxidative stress response required for bacillus Calmette-Guérin direct effects on urothelial carcinoma biology.Loss of bacillus Calmette-Guérin viability adversely affects the direct response of urothelial carcinoma cells to bacillus Calmette-Guérin exposure.Overexpression of tumour-associated carbohydrate antigen sialyl-Tn in advanced bladder tumours.Bacillus Calmette-Guérin vaccination at birth and in vitro cytokine responses to non-specific stimulation. A randomized clinical trial.A case of disseminated Mycobacterium bovis 2 years post-intravesicular Bacillus Calmette-Guérin therapy for superficial urinary bladder cancer.The Dose-Response Relationship of bacillus Calmette-Guérin and Urothelial Carcinoma Cell Biology.Mycobacterium bovis Osteomyelitis of the Thoracic Spine Mimicking a Metastatic Lytic Lesion in a Patient Exposed to Intravesicular Bacille Calmette-Guérin Treatment.Mycobacteria Bovis osteomyelitis following intravesical BCG for bladder cancer.Dynamics of Immune Checkpoints, Immune System, and BCG in the Treatment of Superficial Bladder Cancer.
P2860
Q26744142-682C531F-B6BD-401F-BFAD-EB004E91A2BEQ26770165-DAB95A92-9066-4862-AC15-8BABCD8065D0Q26775977-8C7AF6E9-9D6C-4251-A25A-6AB2B14AB9AFQ26798372-7ECE7D94-274B-4E95-965C-4A094BF9E893Q33563230-759E3655-2608-4D14-A708-9DA5D405EADCQ33711371-5629FA4D-6351-4AB8-A276-60F9544E5A9DQ34054603-A002D3B3-042A-49AA-A63A-F31E04800A6EQ34585331-8E48BE49-F490-472A-80F1-E1B9CEEC8478Q35690511-FEF457FA-733C-4045-ACF3-A37D985E4FB7Q35853865-54BBECB4-633A-435A-9731-AEC3E1CF322CQ35937807-9DE9B90F-91AE-4F11-8D39-34B55D7E4793Q36070462-2C30A693-298E-4B92-BCD9-2B5127A2D9D4Q36095397-49CB3D56-1631-4998-A0C4-E020B4C124CFQ36328010-52B54E32-E796-4DB4-B59D-6FA8B2AD363FQ36939977-26A5357E-D0B9-42AF-AE88-ACD477338E6AQ37094072-98C61131-B153-484B-A483-9B1D1C356715Q37344348-4A68F042-EE98-4C5C-BB64-7DDAEDD15A14Q37392963-B2CBBCE0-5E4D-45A9-BC3C-31CFFF529248Q37540079-A80AF170-A713-45BA-8023-29599590066FQ38232854-90776522-034D-4118-82A3-8CD70F519853Q38251141-65E6B7A5-BEAF-4FD4-85CD-83DB03A1FB25Q38385719-66670F8E-A8E5-4491-8D98-9EBD66713695Q38400759-DDEFDA98-F441-45B2-B925-046F1839F542Q38727522-90291ADB-0B56-48D3-A737-B71967ADF537Q38828413-5A5E24E3-B412-4A62-8B1F-5FA424AE65F1Q38961435-E95B5904-1654-4BB9-9CE1-C6F32FECD6AFQ38984952-503E6D32-D0DA-4D83-8BE4-55B13CC5FC50Q39096174-C55CDB91-ABDC-4D7A-9EBE-A6F5821ABB46Q39169405-9D51C08D-10DD-4EF4-BF44-7E10949C20D3Q40054432-41BE4AC6-97FF-473E-BCEE-DFECC8D6297EQ40147359-179C9A6A-6CD5-4364-A1EA-8735B80013A2Q40180513-89CCE8B3-50C1-4294-9EB3-A37B63503552Q42208452-3B330633-FC93-4563-9F71-9D39E7318F7FQ42374413-D3F78D23-AD67-48EF-B1F0-94D58BBAB957Q47220897-9F92552D-EC94-419C-8F2C-4929352A5B02
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Bladder Cancer Immunotherapy: BCG and Beyond.
@ast
Bladder Cancer Immunotherapy: BCG and Beyond.
@en
type
label
Bladder Cancer Immunotherapy: BCG and Beyond.
@ast
Bladder Cancer Immunotherapy: BCG and Beyond.
@en
prefLabel
Bladder Cancer Immunotherapy: BCG and Beyond.
@ast
Bladder Cancer Immunotherapy: BCG and Beyond.
@en
P2860
P356
P1433
P1476
Bladder Cancer Immunotherapy: BCG and Beyond
@en
P2093
Eric J Askeland
Mark R Newton
P2860
P304
P356
10.1155/2012/181987
P577
2012-06-20T00:00:00Z